Summary We have investigated the effect of the soybean isoflavone genistein on the growth and differentiation of human melanoma cells. Four human melanoma cell lines, either completely lacking or containing different levels of wild-type p53, were treated with genistein in vitro in culture. It has been found that genistein significantly inhibited cell growth and that the chemosensitivity might depend on cellular p53 content. Specifically, the data suggest that high levels of wild-type p53 expression make cells resistant to genistein's growth-inhibitory action. Further support for this observation came from the stable transfection studies in which p53 transfectants expressing high levels of wild-type p53 became resistant to genistein. With respect to cell differentiation, our study showed that genistein increased melanin content and tyrosinase activity and caused the cells to form dendrite-like structures. Cells lacking p53 responded more than cells with p53 to dendrite-like structure formation. We also observed that genistein-induced differentiation involved an increase in tyrosinase mRNA level; the mechanisms by which genistein increases tyrosinase transcripts remain to be elucidated. Genistein treatment of the melanoma cell lines resulted in cell cycle arrest at G2/M check point and no significant apoptosis was observed.
Currently, the incidence of malignant melanoma is on the rise. The increase in the number of melanomas diagnosed has been found to be greater than for any other cancer except lung cancer in women (Brozena et al, 1993) . Melanomas are readily treatable during the early stages of development, but the prognosis is grave once the disease metastasizes. Currently available therapies are not effective in preventing or curing metastatic spread and morbidity in patients with this cancer. Better therapeutic and preventive approaches need to be developed against growth and metastasis of melanoma.
Epidemiological studies suggest that soy consumption may contribute to lower rates of cancers (Nagasawa et al, 1980; Messina and Barnes, 1991; Messina et al, 1994) . One of the hypothesized candidates against malignancy in soybeans is genistein (4',5,7-trihydroxyisoflavone), a major isoflavone of soybean. Several classes of compounds in soybeans, like protease inhibitors, saponins, phytosterols, and isoflavones, have demonstrated anti-cancer activity. The most recent experimental studies, however, suggest that genistein may play a major role in mediating the anti-carcinogenic effects of soybeans (Messina and Barnes, 1991) . Purified genistein inhibited the growth of a wide range of cultured cancer cells like leukaemia, breast and prostate cancer, and lymphoma Kondo et al, 1991; Watanabe et al, 1991; Barnes, 1991, 1993; Pagliacci et al, 1993; Buckley et al, 1993) . In vivo studies also demonstrated that genistein reduced both the incidence and the multiplicity of DMBA-induced mammary tumours and azoxymethane-induced colon tumours in rats (Lamartiniere et al, 1994; Steele et al, 1995) . Among other enzymes, genistein inhibits the activity of protein tyrosine kinase (PTK) and topoisomerase II (Akiyama et al, 1987; Markovits et al, 1989) . Mechanistically, genistein treatment caused DNA strand breakage, and DNA breaks were found to be protein linked Kiguchi et al, 1990) . Under certain treatment conditions, genistein caused cell cycle arrest and apoptotic cell death in several leukaemia cell lines (Traganos et al, 1992; Spinozzi et al, 1994 ). The precise molecular mechanism(s) by which genistein exerts its effects against tumour cells are still not clear.
Recent studies show that both soy and genistein are effective against skin cancer. Consumption of soybean diets delayed the onset of skin tumours induced by nitroquinoline-N-oxide and 12-O-tetradecanoyphorbol-13-acetate (TPA) (Troll et al, 1979) . In a two-stage mouse skin carcinogenesis experiment, the soybean milk protein reduced both the incidence and the volume of skin tumours (Limtrakul et al, 1993) . Topically applied genistein has been found to reduce the number of skin carcinomas induced by DMBA and TPA in CDI mice . The topical application of genistein also inhibited TPA-induced increases in hydrogen peroxide production in a mouse skin model (Wei et al, , 1995 . A more recent study showed that dietary genistein significantly enhanced antioxidant enzyme activities in skin (Cai et al, 1996) .
In the present study, we examined the effect of genistein on the growth and differentiation of melanoma that arises from normal melanocytes commonly located in skin. We used four human melanoma cell lines that either completely lack or contain different levels of wild-type p53 as described earlier (Rauth et al, 1994a, b) . The differentiated state of the cells was characterized morphologically and by tyrosinase gene expression and melanin content. The results showed that genistein significantly inhibited growth and induced differentiation of human melanoma in culture. The results also suggested that the chemosensitivity of the cells might depend on cellular p53 content. Cells either lacking or containing low p53 protein levels were more sensitive to genistein-induced growth arrest than cells with high p53. Further support for these observations came from gene transfer studies, in which stable transfectants expressing high levels of wild-type p53 became resistant to genistein's growth-inhibitory action. With respect to differentiation, we found that melanoma cells not expressing p53 were more sensitive to genistein-induced dendrite-like structure formation than cells expressing high p53. Our study also showed that genistein-induced differentiation was associated with an increase in tyrosinase mRNA level. The mechanism(s) by which genistein increases tyrosinase transcripts remain(s) to be elucidated. Genistein treatment of the melanoma cell lines resulted in arrest of G2/M check point of cell cycle distribution and no significant apoptosis was observed.
MATERIALS AND METHODS Cells and media
The human melanoma cell lines, UISO-MEL-6, UISO-MEL-4, UISO MEL-7 and UISO-MEL-8, established and characterized in our laboratory (Rauth et al, 1994a, b) , have been used in the present study. All cells were maintained in MEM-H [minimum essential medium with Hanks' balanced salt solution (Gibco, Grand Island, NY, USA)] containing fetal calf serum (2%), L-glutamine (1%), non-essential amino acids and penicillin-streptomycin (0.2%).
Plasmids and reagents
The human wild-type p53 expression plasmid, pC53-SN3, and the expression vector without p53 cDNA, pCMVNeo, originally constructed by Bert Vogelstein (Baker et al, 1990) 
Transfection experiments
To isolate cells stably transfected with human wild-type p53 expression plasmid pC53-SN3, UISO-MEL-4 cells were co-transfected with plasmids pC53-SN3 and pIRVGalNeo as described earlier (Rauth et al, 1993) . Three days after transfection, the cells were subcultured in the presence of 1 mg ml G418 (Sigma Chemical Co.). The selective media with G418 was replaced every 3 days, and the colonies that appeared after 10-14 days were pooled and subcultured for further analysis. The stable transfectant was designated as UISO-MEL-4WP. As a control, cells stably transfected with the expression vector were also isolated similarly.
Western blot analysis
The melanoma cell lines were analysed for p53 protein level by Westem blot analysis. These cells were then lysed in lysis buffer containing 50 mM Tris (pH 8.0), 250 mm sodium chloride and 0.1% Nonidet p-40 as described (Kichina et al, 1996) . The cell extracts containing equal amounts of protein (150 jg) were separated on a sodium dodecyl sulphate (SDS)-12.5% polyacrylamide gel. The proteins were transferred electrophoretically to a nitrocellular membrane, and the p53 proteins in the blot were detected with a 1:200 dilution of p53 monoclonal antibody Ab-2 (pAbl801, Oncogene Science) and the enhanced chemiluminescence system (Amersham).
Tyrosinase expression by reverse transcription and polymerase chain reaction (RT-PCR)
The human melanoma cell lines were analysed for tyrosinase expression at the mRNA level by reverse transcription of the total cellular RNA and PCR amplification of the reverse-transcribed tyrosinase transcript using primers specific for human tyrosinase sequences. The PCR amplification of the reverse-transcribed RNA was performed in a 100-gl volume with 2.5 U of Taq DNA polymerase (Promega), using an Eri Comp DNA thermocycler following the procedure described previously (Kichina et al, 1996) . The sequences of the primers used to amplify tyrosinase cDNA sequences were: primer 1: 5'-TAGGACCTGCCAGTTGCCTTTCT-3' (sense); primer 2: 5'-AAGGCATTGTGCATGC-3' (antisense). The sequences of the primers were obtained from the published report (Powers et al, 1994) and were synthesized on an ABI model 394 DNA synthesizer. The primer 1 is located on exon 1, whereas primer 2 is located on exon 2 of the tyrosinase gene, and these primers amplify a 840-bp cDNA fragment. The control PCR amplification reaction mixture contained the reagent mixture for PCR amplification without the added cDNA.
p53 expression by RT-PCR p53 mRNA was analysed by RT-PCR of total cellular RNA from the stable transfectants as described earlier (Kichina et al, 1996) . The sequences of the primers used to amplify p53 cDNA are spaced 1225 nucleotides apart and yield a full-length cDNA fragment. Primer 1: 5'-AGACTGCCTTCCGGGTCACT-3'; primer 2: 5'-GGGAACAAAGAAGTGGAGAAT-3'. P2-Microglobulin (V2 m) mRNA, used as an internal control, was also analysed by RT-PCR. The sequences of the primers used to amplify I2-microglobulin were obtained from published sequences (Noonan et al, 1990) and yielded a 120-bp cDNA fragment.
Flow cytometry Melanoma cells (1 x 107) were cultured in the presence of dimethyl sulphoxide (DMSO) or genistein for 0, 24, 44 and 72 h. Cells were harvested, fixed with ethanol and flow cytometry was performed after treatment with trypsin and RNAase A as described previously (Pisha et al, 1995) .
RESULTS
Differential effect of genistein on melanoma growth in vitro To investigate genistein's effects on melanoma cells, we have used four cell lines (UISO-MEL-6, UISO-MEL-4, UISO-MEL-7 and UISO-MEL-8) that either lack or contain different levels of wildtype p53 (Rauth et al, 1994a, b) . In our previous study, we have analysed ten melanoma cell lines for p53 alterations at the DNA, RNA and protein levels (Rauth et al, 1994a Immunocytochemical analysis using antibody specific for wildtype and mutant p53 protein agreed with the DNA and RNA analysis data. The cytogenetic analysis of these cell lines showed that 17p, where p53 is located, is missing in UISO-MEL-6 cell line owing to isochromosome formation (Rauth et al, 1994b) . Taken were quantified by Western blot analysis. As shown in Figure 1 , different levels of p53 protein are present in four cell lines that agree with our previous data. To test the functionality of endogenous wild-type p53 protein in these cell lines, a number of experiments using transient transfection approaches and a construct containing CAT reporter gene ligated to p53-responsive p21 promoter sequences have been done. Our preliminary experiments showed that endogenous p53 in these cell lines might be functional and could induce CAT gene expression from a p53-responsive element (data not shown).
The four cell lines, either lacking or containing various p53 levels, were treated with different concentrations of genistein, and the cell numbers were counted for 9 days (renewing the culture with fresh media every 3 days). As shown in Figure 2, Figure  5A , the stable transfectants, MEL-4 WP, expressed a high level of p53 protein compared with the parental MEL-4 cells.
To determine whether p53 mRNA is transcribed from the transfected plasmid, transfectants were analysed for p53 mRNA levels by reverse transcription and polymerase chain reaction. As shown in Figure SB, 
DISCUSSION
The data presented in this report demonstrate that genistein can arrest growth and enhance differentiation of metastatic melanoma cells; more importantly, the chemosensitivity of these cells may be regulated by cellular p53. We used four cell lines that have been well characterized for p53 at DNA, RNA and protein levels (Rauth et al, 1994a, b) . The results presented here showed that the growth of cells either negative (UISO-MEL-6) or low (UISO-MEL-4) in wild-type p53 was almost completely inhibited when treated with genistein. In contrast, only a small decrease in growth rate was observed in melanoma cells containing a high level of wild-type p53.
The melanoma cell lines were originally derived from the biopsies of different patients (Rauth et al, 1994b) and may differ in factors besides the endogenous p53 content. To investigate whether the differential effect of genistein on cell growth is related to the levels of endogenous p53, we stably transfected the melanoma cell line MEL-4 with wild-type p53 expression plasmid. The functionality of wild-type p53 expressed in the stable transfectant was tested by an increase in endogenous p21 expression. To determine the effects of genistein, parental cells containing very low levels of endogenous wild-type p53, and the transfectants expressing high levels of p53, were treated with different doses of genistein. The data presented in Figure 5 clearly show that p53 transfectants became significantly less sensitive than the parental cells to genistein's growth-inhibitory effects.
As a corollary to our observations, a recent study reported that genistein induced endogenous p53 levels in several tumour cell lines (El-Deiry et al, 1994) . Previous studies have demonstrated that genistein caused single-and double-strand DNA breaks in tumour cells Kiguchi et al, 1990 Significantly more dendritic structures were observed in p53-negative cells compared with those in p53-positive cells. Genisteininduced differentiation involved an increase in tyrosinase expression at the mRNA level. The mechanism(s) by which the tyrosinase mRNA level is increased are still not known. Recently, we demonstrated that bromodeoxyuridine (BrdU) , which suppresses differentiation in melanoma, suppressed tyrosinase expression at the mRNA level (Rauth et al, 1990) . The suppression of tyrosinase mRNA involved suppression of tyrosinase promoter activity (Rauth et al, 1993) . It is possible that genistein mediates its effects through similar mechanism(s), but additional experiments are required to investigate these possibilities.
In summary, the present observations show that genistein is able to inhibit growth and induce differentiation in human melanoma cells in vitro. The effects of genistein may depend on the levels of endogenous p53 in the cells. It is not surprising that we found p53-negative cells were more sensitive to genistein's effects. p53 is known to induce DNA repair enzymes, and cells containing wildtype p53 may have repair of the DNA damage caused by genistein treatment. Tumour cells, either deficient in p53 or with very low doses of it, replicate through the damage and are more susceptible to genistein's effects. A recent report by Elledge et al (1995) , who noted that patients with breast cancer in whom there were p53-negative cells tended to receive greater benefit from chemotherapy with different drugs, including DNA-damaging agents, supports our observation. Genistein inhibits the growth of tumour cells in vivo (Lamartiniere et al, 1994) and has been proved to be nontoxic in animals (Faber et al, 1991; Schweigerer et al, 1992) . Both soybean and genistein have been found to be effective in reducing skin carcinogenesis (Troll et al, 1979; Limtrakul et al, 1993; Bowen et al, 1993; Wei et al, 1993 Wei et al, , 1995 Cai et al, 1996) . These reports provide a good basis for further evaluation of genistein in vivo for treating or preventing melanoma that contains cells with different p53 status.
